CRYSTAL primary tumor location post hoc analysis: Efficacy in patients with left- and right-sided RAS wild-type mCRC5
RAS wild-type subpopulation by primary tumor location (n=364): CRYSTAL regimen (n=175); FOLFIRI alone (n=189)
Select Important Safety Information
ERBITUX can cause interstitial lung disease (ILD). ILD, which was fatal in one case, occurred in <0.5% of 1570 patients receiving ERBITUX in clinical trials. Monitor patients for signs and symptoms of pulmonary toxicity. Interrupt or permanently discontinue ERBITUX for acute onset or worsening of pulmonary symptoms. Permanently discontinue ERBITUX for confirmed ILD.